Nearly half of the US is slipping toward recession. However, wealthy asset holders are feeling a much “nerfed” impact compared to households strained by debts.Nearly half of the US is slipping toward recession. However, wealthy asset holders are feeling a much “nerfed” impact compared to households strained by debts.

Recession misses America’s asset owners while hitting everyone else

2025/11/17 17:30

Nearly half of the United States is slipping toward recession. However, according to financial newsletter Kobeissi, wealthy asset holders are feeling a much “nerfed” impact compared to households strained by rising debts, stagnant wages, and job cuts. 

The Kobeissi Letter, sharing a chart from Moody Analytics, reported that 23 states are now in recession or at high risk of entering one. Those states represent almost a third of total US economic output, a deterioration from September’s findings which counted 22 states, with the addition of Michigan.

23 US states are fighting a losing battle with recession

Struggling parts of the country are states in the Midwest, Northeast, and Northwest, where those marked in red include Washington, Oregon, Montana, Wyoming, South Dakota, Minnesota, Iowa, Michigan, Illinois, Virginia, Connecticut, and Maine. 

States supposedly in the clear include Texas, Florida, Louisiana, Arizona, North Carolina, and Georgia. Those mentioned to be in the “water,” which meant they are holding steady but no longer posting meaningful growth, were California, New York, Nevada, Pennsylvania, and Maryland. 

According to the report, the nation’s two largest state economies California and New York are no longer expanding at earlier rates, and MarketWatch economist Mark Zandi believes the two could turn the whole US into recession if the situation deteriorates. 

Moody Analytics’ research also found that the top 10% of households control about two-thirds of the nation’s wealth, while the bottom half of Americans hold less than 3%.

The wealth of asset holders, the struggle of hand-to-mouth workers

Households with investment portfolios, rising home values, or business equity are benefiting from appreciating financial markets. Meanwhile, families whose spending goes primarily toward rent, insurance, utilities, and groceries are struggling because prices are not coming down, and wages are not getting any better.

“While there is some distress at the household level, in line with that K-shaped economy where the rich get richer and the poor get poorer. The macro picture is fairly bright,” wrote Bankrate senior industry analyst Ted Rossman in a note to investors last Wednesday.

Total US household debt reached a record $18.59 trillion this year, with heavy reliance on loans for cars, education, homes, and day-to-day living. Credit bureau Experian estimated that Americans owed $17.57 trillion in the third quarter of 2024, a 2.4% increase from the previous year and more than $105,000 in liabilities per consumer.

Millennials carried the largest total average debt at $371,864 mostly from home loans. But when mortgages are excluded, Generation X leads instead, owing about $68,038 in non-housing balances. Without the ability to buy appreciating assets, lower-income Americans are dependent on credit.

“If you spend on rent, groceries, insurance, utilities, you will feel like the economy is collapsing. But if you spend on stocks, real estate, 401(k), business ownership, you feel like the economy is booming,” said one trader on social platform X.

Unemployment, job losses, and inflation takes a toll on the US economy

According to data collected by the Economic Policy Institute from state labor departments, there is a dramatic surge in continued unemployment insurance filings across Washington, Maryland, Virginia, Connecticut, and Oregon.

Federal claims in DC jumped more than 1,000% compared with 2024’s tallies, while Maryland recorded an increase of more than 500%. When looking at claims in all state-managed programs, the year-over-year gains for DC, Virginia, and Maryland were 53%, 29%, and 25% respectively.

US employers cut more than 150,000 jobs last month, the largest October reduction in more than twenty years. This will certainly become a talking point in the Federal Reserve’s December 9-10 FOMC meeting, after the longest US government shutdown blinded Jerome Powell and his camp with delayed key economic indicators. 

Traders using the CME FedWatch Tool have reduced the probability of a December interest rate cut to below 50%, down from the nearly 96% probability priced in just one month ago.

Investors had hoped for another rate reduction to support borrowing, consumer spending, and corporate investment during the slowdown. However, several Fed officials insist inflation is too high to justify more cuts at the end of 2025.

Get seen where it counts. Advertise in Cryptopolitan Research and reach crypto’s sharpest investors and builders.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Novo Nordisk cuts cash prices for Wegovy, Ozempic

Novo Nordisk cuts cash prices for Wegovy, Ozempic

The post Novo Nordisk cuts cash prices for Wegovy, Ozempic appeared on BitcoinEthereumNews.com. Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.  The Danish drugmaker is lowering the price of the drugs for existing cash-paying patients to $349 per month from $499 per month. But Novo Nordisk said the cash-pay cost of the highest dose of Ozempic will remain $499 per month.  Also on Monday, Novo Nordisk launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. After that period, people move to the new standard monthly direct-to-consumer price. The company’s introductory offer ends on March 31.  The announcements come days after President Donald Trump struck deals with Novo Nordisk and chief rival Eli Lilly to make their popular GLP-1 drugs easier for Americans to access and afford. Those agreements will involve cutting the prices the government pays for the drugs, introducing Medicare coverage of obesity drugs for the first time for certain patients and offering discounted medicines on the government’s new direct-to-consumer website launching in January called TrumpRx.  “Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations, said in a release. “It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like…
Share
BitcoinEthereumNews2025/11/17 21:30